

IN THE SPECIFICATION:

Please delete the first paragraph of the application following the title on page 1, lines 13-16, and replace it with the following:

K1 This application claims priority to U.S. Patent Applications Serial No. 07/460,852 filed February 21, 1990 and 07/065,734 filed June 24, 1987, both abandoned.

IN THE CLAIMS:

Please amend the claims pursuant to 37 C.F.R. 1.121 as follows (see the accompanying "marked up" version pursuant to 1.121):

Please cancel claims 30, 34, 36, 39 and 41 ✓ ✓ ✓ ✓ ✓ amend the remaining claims as follows:

K2 29. (Amended) A method for the treatment of a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human presenting with said autoimmune response, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen

K2
selected from the group consisting of autoantigens specific for said autoimmune disease, said suppression comprising elicitation of suppressor T cells specific to said administered antigen.

31. (Unchanged) The method of claim 29 wherein said autoantigen is administered orally.

32. (Unchanged) The method of claim 29 wherein said autoantigen is administered enterally.

33. (Unchanged) The method of claim 29 wherein said autoimmune disease is multiple sclerosis.

K3
35. (Amended) A method of treating a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human presenting with said autoimmune response, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen selected from the group consisting of autoantigens specific for said autoimmune disease.
